McBrearty A, McCallion K, Moorehead R J, McAllister I, Mulholland K, Gilliland R, Campbell W J
Department of General Surgery, Ulster Hospital, Dundonald, Belfast, BT16 1RH.
Ulster Med J. 2016 Sep;85(3):178-181.
In patients with locally advanced or low rectal cancers, long-course chemoradiotherapy (LCCRT) is recommended prior to surgical management. The need for restaging afterwards has been questioned as it may be difficult to interpret imaging due to local tissue effects of chemoradiotherapy. The purpose of this study was to determine if restaging affected the management of patients receiving long-course chemoradiotherapy for rectal cancer.
A retrospective review of patients with rectal cancer discussed at the South Eastern Health and Social Care Trust Lower Gastrointestinal Multi-Disciplinary Team Meeting (LGIMDT) in 2013 who had received long-course chemoradiotherapy was performed. Patients were identified from the Trust Audit Department, LGIMDT notes and patient records. Imaging results and outcomes from meetings were obtained through the Northern Ireland Picture Archiving and Communications System (NIPACS) and Electronic Care Record (ECR). Data including patient demographics, initial radiological staging and LGIMDT discussion, restaging modality and result, outcome from post-treatment LGIMDT discussion and recorded changes in management plans were documented using a proforma.
Seventy-one patients with rectal cancer were identified as having LCCRT in 2013 (M:F 36:35; age range 31 - 85 years). Fifty-nine patients were restaged following long-course treatment with computed tomography (CT) and magnetic resonance imaging (MRI). Twelve patients did not undergo restaging. Data was not available for 6 patients, one patient underwent emergency surgery, two patients were not fit for treatment, one failed to attend for restaging and two patients died prior to completion of treatment. Of the 59 patients restaged, 19 patients (32%) had their management plan altered from that which had been proposed at the initial LGIMDT discussion. The most common change in plan was not to operate. Ten patients had a complete clinical and radiological response to treatment and have undergone intensive follow-up. Nine patients had disease progression, with 3 requiring palliative surgery and 6 referred for palliative care.
Of those patients who were restaged, 32% had their management plan altered from that recorded at the initial LGIMDT discussion. Seventeen per cent of patients in this group had a complete clinical and radiological response to treatment. Fifteen percent demonstrated disease progression. We recommend, therefore, that patients with rectal cancer be restaged with CT and MRI following long-course chemoradiotherapy as surgery may be avoided in up to 27% of cases.
对于局部晚期或低位直肠癌患者,建议在手术治疗前进行长程放化疗(LCCRT)。放化疗后重新分期的必要性受到质疑,因为放化疗的局部组织效应可能导致难以解读影像学检查结果。本研究的目的是确定重新分期是否会影响接受直肠癌长程放化疗患者的治疗管理。
对2013年在东南健康与社会护理信托基金下消化道多学科团队会议(LGIMDT)上讨论过的接受长程放化疗的直肠癌患者进行回顾性研究。从信托基金审计部门、LGIMDT记录和患者记录中识别患者。通过北爱尔兰图像存档与通信系统(NIPACS)和电子护理记录(ECR)获取会议的影像学检查结果和结果。使用一份表格记录包括患者人口统计学、初始放射学分期和LGIMDT讨论、重新分期方式和结果、治疗后LGIMDT讨论的结果以及记录的管理计划变化等数据。
2013年确定71例直肠癌患者接受了LCCRT(男:女为36:35;年龄范围31 - 85岁)。59例患者在长程治疗后通过计算机断层扫描(CT)和磁共振成像(MRI)进行了重新分期。12例患者未进行重新分期。6例患者的数据不可用,1例患者接受了急诊手术,2例患者不适合治疗,1例未参加重新分期,2例患者在治疗完成前死亡。在59例重新分期的患者中,19例(32%)的管理计划与初始LGIMDT讨论中提出的计划不同。最常见的计划改变是不进行手术。10例患者对治疗有完全的临床和影像学反应,并接受了强化随访。9例患者疾病进展,其中3例需要姑息性手术,6例转诊接受姑息治疗。
在重新分期的患者中,32%的管理计划与初始LGIMDT讨论中记录的不同。该组中17%的患者对治疗有完全的临床和影像学反应。15%的患者疾病进展。因此,我们建议直肠癌患者在长程放化疗后用CT和MRI进行重新分期,因为高达27%的病例可能避免手术。